Why 150,000+ Southeast Asians Chose China for Medical Care in 2025 (And You Might Too)

Of all the trends I’ve watched in China’s medical tourism boom over the past couple of years, the surge from Southeast Asia is the one that’s caught me off guard — and it’s barely covered in English-language media.

In 2025, more than 150,000 patients from countries like Indonesia, Malaysia, Vietnam, Thailand, the Philippines, Myanmar, Cambodia, Laos, and Singapore traveled to China for medical care. That’s a 73.6% jump from three years ago. At Hainan’s Boao Lecheng Medical Pilot Zone alone, Southeast Asian patients made up over 60% of international visits, with year-on-year growth hitting 800% in the first quarter of 2026.

This isn’t a trickle — it’s a wave. And understanding why tells you a lot about where China’s medical tourism industry is heading.

Why Southeast Asian Patients Are Choosing China

From chats with hospital international departments and patients themselves, here are the main drivers:

1. It’s Close — Really Close

Kunming in Yunnan Province is just a 2-hour flight from Bangkok, 3 hours from Kuala Lumpur, and 4 hours from Jakarta. Guangzhou and Shenzhen are similarly easy to reach. For many Southeast Asian patients, flying to China for treatment takes less time than getting to their own country’s capital.

Kunming has become a key hub. Its medical facilities, combined with Yunnan’s mild weather and lower costs, make it a great option for patients from Myanmar, Laos, Cambodia, and Thailand. Bangladeshi patients, who’ve been diverted from India due to political tensions, are increasingly heading to Kunming for spinal surgery and other procedures at prices as low as $1,400.

2. It’s Cheaper Than Regional Alternatives

For many procedures, China is now cheaper than or comparable to Singapore and Thailand — and way more affordable than what some ASEAN patients face at home.

A comprehensive health checkup that costs $500–$1,000 in Singapore runs $200–$500 in China. Cancer treatment at Boao Lecheng, with access to drugs not yet approved elsewhere in Asia, often costs 40–60% less than equivalent care in Singapore or Thailand. Even after factoring in travel, the savings are huge.

3. Access to Cutting-Edge Treatments

Boao Lecheng is a major draw. This special medical zone in Hainan lets patients use drugs and medical devices approved overseas before they’re okayed in China — and often before they’re available anywhere in Asia. As of mid-2026, over 560 innovative drugs and devices have been introduced through the zone, including CAR-T therapies, advanced immunotherapy drugs, and next-gen medical devices.

For Southeast Asian patients with limited options at home — especially for cancer, rare diseases, and complex conditions — Boao Lecheng offers a real alternative.

4. Visa-Free and Simplified Entry

China’s expanding visa-free policies have made traveling for medical treatment much easier. Citizens of most ASEAN countries can now enter China without a visa for stays of 15–30 days, which covers most routine procedures. The 240-hour (10-day) transit visa-free policy, available at 65 ports of entry, is popular among medical tourists for short-term treatment trips.

For Boao Lecheng specifically, there’s a 48-hour expedited medical visa, making last-minute trips possible.

Most Popular Treatments Among Southeast Asian Patients

• Cancer treatment: The #1 reason SEA patients come to China, especially for CAR-T therapy, proton therapy, and immunotherapy drugs at Boao Lecheng. Hospital partners include Hainan Boao Super Hospital and the First Affiliated Hospital of Hainan Medical University.
• Health checkups: Comprehensive health screenings at 50–70% less than Singapore or Hong Kong prices. Many patients combine a checkup with a vacation in Hainan or Yunnan.
• Pediatric care: Growing fast, with hospitals like Shenzhen Children’s Hospital (over 100,000 cross-border pediatric patients since 2023) and Zhejiang University Children’s Hospital seeing more families from Indonesia, Malaysia, and Singapore.
• TCM and wellness: Especially popular with Indonesian and Malaysian patients of Chinese descent, who are familiar with TCM concepts and seek treatment at established TCM hospitals.
• Cosmetic surgery: A smaller but growing segment. China’s cosmetic surgery is pricier than Korea’s but offers better post-op follow-up access for SEA patients due to proximity.
• Cardiac and orthopedic surgery: Increasing numbers from Vietnam, Myanmar, and Cambodia, where local options are limited or expensive.

Country-Specific Trends

• Indonesia: The largest SEA source market. Strong demand for cancer treatment, health checkups, and TCM. Jakarta-Haikou (Boao) direct flights make Hainan the top choice.
• Malaysia: Malaysia has its own solid healthcare system, but patients come to China for TCM, cancer treatment, and access to drugs not available at home. The Chinese diaspora connection is strong here.
• Vietnam: Rapid growth in border-area medical tourism to Yunnan and Guangxi. Popular treatments: health checkups, dental care, and minor surgeries.
• Myanmar: Kunming is the top destination. Patients come for spinal surgery, cancer treatment, and general medical care, often diverted from India due to visa restrictions.
• Singapore: Surprisingly active for a small country. Patients come for CAR-T therapy (where Singapore has limited options), organ transplantation, and TCM.
• Thailand: The smallest SEA source market because Thailand’s own medical tourism industry is so strong. The flow is mostly Chinese patients going to Thailand, not the other way around.

Real Patient Story

A patient from Indonesia with advanced cancer was told by doctors in Jakarta that treatment options were limited. Through a family connection, she learned about Boao Lecheng. Within two weeks, she’d sent her medical records, received a treatment plan, obtained a visa, and flown to Hainan. The treatment she got — a mix of immunotherapy and targeted therapy — wasn’t yet available in Indonesia. After three months, her tumors had shrunk significantly. Her total cost, including all treatment, accommodation, and flights, was less than what she’d been quoted for limited options in Singapore.

Stories like this are becoming routine rather than exceptional. For many Southeast Asian patients, China is no longer a backup — it’s the first choice.

The Future

China’s medical tourism infrastructure for Southeast Asian patients is still evolving. Language support, payment systems, and post-discharge follow-up all need work. But the direction is clear: with over 150,000 SEA patients already coming annually, and Boao Lecheng seeing 800% growth, this trend is only accelerating.

For Southeast Asian patients considering medical treatment abroad, China offers a combination of geographic proximity, advanced medical technology, and cost competitiveness that no other destination can match. The wave is real, and it’s just getting started.